Used in targeted therapy for HER2-positive cancers, particularly breast and gastric cancers. Binds to the HER2 receptor with high specificity, inhibiting tumor cell growth and promoting immune-mediated destruction of cancer cells. Its bispecific design enables dual binding to different HER2 epitopes, enhancing antitumor activity and internalization. Employed in clinical settings for patients with advanced or metastatic disease who have limited treatment options. Also being investigated in combination with chemotherapy and other immunotherapies to improve response rates. Shows promise in overcoming resistance seen with other HER2-targeted agents.